Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer

NCT03284957 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
136
Enrollment
INDUSTRY
Sponsor class

Stopped Sponsor decision to prematurely stop the study, not linked to any safety concern.

Conditions

Interventions

Sponsor

Sanofi